aTyr Readies Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma is launching a Phase 3 clinical trial to evaluate the safety and effectiveness of efzofitimod (ATYR1923) in people with pulmonary sarcoidosis. Expected to begin later this year, the primary goal of the study — dubbed EFZO-FIT — will be a reduction in therapeutic corticosteroids, which…